-
Product Insights
CTI SSI FOOD – Amarillo Food Processing Facility – Texas
Equip yourself with the essential tools needed to make informed and profitable decisions with our CTI SSI FOOD - Amarillo Food Processing Facility - Texas report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
Weiguang Huitong CTI – Chuxiong Yifeng Cultural Tourism Health Resort – Yunnan
Equip yourself with the essential tools needed to make informed and profitable decisions with our Weiguang Huitong CTI - Chuxiong Yifeng Cultural Tourism Health Resort - Yunnan report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...
-
Company Profile
![]()
CTI BioPharma Corp – Company Profile
CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company that acquires, develops, and commercializes novel therapies for a range of blood-related cancers. Its lead product, Pacritinib is intended for the treatment of patients with myeloproliferative diseases. Its product pipeline includes PACIFICA for the treatment of myelofibrosis patients with severe thrombocytopenia, PAC203 for the patients with ruxolitinib therapy failure, PRE-VENT for COVID-19, PERSIST 1 for all platelets count and PERSIST 2 for platelets counts less than thousand. Its commercialized product, Vonjo...
Add to Basket -
Thematic Analysis
New![]()
Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes in Q2 2023 – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q2 2023 in the Pharma Sector
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Belvarafenib in Metastatic Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Belvarafenib in Metastatic Melanoma Drug Details: Belvarafenib is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CGX-1321 in Esophageal Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CGX-1321 in Esophageal Cancer Drug Details: CGX-1321 is under development for the treatment of...
-
Product Insights
Anqing CTI – Tianqian Expressway: Anqing-Qianshan Section – Anhui
Equip yourself with the essential tools needed to make informed and profitable decisions with our Anqing CTI - Tianqian Expressway: Anqing-Qianshan Section - Anhui report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Isunakinra in Bile Duct Cancer (Cholangiocarcinoma)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Isunakinra in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Isunakinra (EBI-005) was under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TCN-201 in Synovial Sarcoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TCN-201 in Synovial Sarcoma Drug Details: TCN-201 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – KITE-222 in Primary Mediastinal B-Cell Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KITE-222 in Primary Mediastinal B-Cell Lymphoma Drug Details: KITE-222 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Naptumomab Estafenatox in Metastatic Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Naptumomab Estafenatox in Metastatic Ovarian Cancer Drug Details:ABR-217620 (anyara, naptumomab estafenatox) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Brexucabtagene autoleucel in Chronic Lymphocytic Leukemia (CLL)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Brexucabtagene autoleucel in Chronic Lymphocytic Leukemia (CLL) Drug Details: Brexucabtagene Autoleucel (Tecartus) is a...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pacritinib in Chronic Myelomonocytic Leukemia (CMML)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pacritinib in Chronic Myelomonocytic Leukemia (CMML) Drug Details: PacritInib (Vonjo) is an anti neoplastic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pacritinib in Peripheral T-Cell Lymphomas (PTCL)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pacritinib in Peripheral T-Cell Lymphomas (PTCL) Drug Details: PacritInib (Vonjo) is an anti neoplastic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pacritinib in Sezary Syndrome
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pacritinib in Sezary Syndrome Drug Details: PacritInib (Vonjo) is an anti neoplastic agent. it...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pacritinib in Mycosis Fungoides
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pacritinib in Mycosis Fungoides Drug Details: PacritInib (Vonjo) is an anti neoplastic agent. it...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pacritinib in Graft Versus Host Disease (GVHD)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pacritinib in Graft Versus Host Disease (GVHD) Drug Details: PacritInib (Vonjo) is an anti...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pacritinib in Cutaneous T-Cell Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pacritinib in Cutaneous T-Cell Lymphoma Drug Details: PacritInib (Vonjo) is an anti neoplastic agent....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pacritinib in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pacritinib in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Drug Details: PacritInib (Vonjo) is an anti...
-
Company Profile
![]()
Clarus Therapeutics Holdings Inc – Company Profile
Clarus Therapeutics Holdings Inc (Clarus Therapeutics) is a pharmaceutical company that develops and markets oral drugs for the treatment of testosterone deficiency and hypogonadism. The company develops JATENZO, a proprietary softgel capsule that contains a testosterone (T) prodrug and T undecanoate formulated to foster absorption via the intestinal lymphatic system. Its oral product eliminates the risk of T transfer to women, and children associated with the T gels. CTI also develops T replacement therapies. It partners with pharmaceutical companies for...
Add to Basket
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.